Literature DB >> 27670878

Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy.

Sadhna Verma1, Andrew B Rosenkrantz2, Peter Choyke3, Steven C Eberhardt4, Scott E Eggener5, Krishnanath Gaitonde6, Masoom A Haider7, Daniel J Margolis8, Leonard S Marks9, Peter Pinto10, Geoffrey A Sonn11, Samir S Taneja12.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 27670878     DOI: 10.1007/s00261-016-0920-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


× No keyword cloud information.
  4 in total

1.  Predictors for the detection of prostate cancer and clinically significant prostate cancer using TRUS-guided biopsy in patients with negative initial biopsy results.

Authors:  Sangjun Yoo; Juhyun Park; Sung Yong Cho; Min Chul Cho; Ja Hyeon Ku; Hwancheol Son; Cheol Kwak; Hyeon Hoe Kim; Hyeon Jeong
Journal:  World J Urol       Date:  2018-03-01       Impact factor: 4.226

Review 2.  The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.

Authors:  Ariel A Schulman; Christina Sze; Efrat Tsivian; Rajan T Gupta; Judd W Moul; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

3.  Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.

Authors:  Abhinav Sidana; Matthew J Watson; Arvin K George; Ardeshir R Rastinehad; Srinivas Vourganti; Soroush Rais-Bahrami; Akhil Muthigi; Mahir Maruf; Jennifer B Gordetsky; Jeffrey W Nix; Maria J Merino; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Urol Oncol       Date:  2018-05-10       Impact factor: 3.498

4.  Electrical conductivity-based contrast imaging for characterizing prostatic tissues: in vivo animal feasibility study.

Authors:  Yong Soo Cho; Young Hoe Hur; Hyun Ju Seon; Jin Woong Kim; Hyung Joong Kim
Journal:  BMC Urol       Date:  2019-10-21       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.